The purpose of the study is to evaluate the effectiveness of Brexanolone, delivered intravenously over a continuous 24-hour period, to treat PTSD in non-veteran premenopausal women.

You may qualify for this study if you meet the following criteria.

Inclusion Criteria:

• Female
• 18-50 years old
• Premenopausal
• Trauma is not from combat
• In good physical health
• Willing to use effective birth control (complete abstinence, Intrauterine device, Birth control pills, or condoms) during participation in the study and 30 days afterward
•  

Exclusion Criteria:

• Pregnant, nursing, or less than 6 months postpartum
• History of psychotic disorders
• History of seizure disorders
• Substance use disorder in the past 6 months

First, there will be a screening, which involves the following:

• physical examination, including height and body weight,
• vital signs,
• blood and urine collection for clinical laboratory testing, including pregnancy testing and drug & alcohol screening,
• ECG, and
• psychiatric assessments.

Participants who qualify will be admitted to the hospital for 1 overnight stay. During that time, participants will receive an intravenous Brexanolone infusion continuously for 24 hours.

Participants will then have 5 follow-up visits on Day 7, Day 14, Day 30, Day 60, and Day 90 after the infusion is completed.

There is no cost for you to participate in our research study.